Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study

Blood Cancer J. 2020 Jun 8;10(6):66. doi: 10.1038/s41408-020-0333-2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Arterial Occlusive Diseases / blood*
  • Arterial Occlusive Diseases / etiology
  • Arterial Occlusive Diseases / prevention & control
  • Cholesterol / blood*
  • Female
  • Humans
  • Imidazoles / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Lipoproteins, LDL / blood*
  • Male
  • Middle Aged
  • Protective Factors
  • Pyridazines / therapeutic use*
  • Triglycerides / blood*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Lipoproteins, LDL
  • Pyridazines
  • Triglycerides
  • ponatinib
  • Cholesterol